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FFP has occasionally been reported to generate an immune
response to RBC antigens (e.g., anti-D and anti-Fya). The Council of
Europe requires that each unit of FFP have less than 6 × 109/L RBCs.
However, there is considerable variation internationally in the
method of production and the level and assessment of RBC
contamination of FFP. This study reports the case of a 63-year-old
group B, D– man who received multiple transfusions of D– blood
products over a 4-month period. Seven months later the patient’s
antibody screen remained negative and he was transfused with
seven units of D– RBCs and six units of FFP, four of which were D+.
Two months later anti-D, -E, and -K were detected in his plasma.
Although the anti-E and anti-K could have resulted from transfusion
of antigen-positive RBCs, the anti-D could have resulted only from
transfusion of the D+ FFP. The D status of FFP is currently not
considered when selecting products for transfusion even though
the D antigen is highly immunogenic and the level of RBC
contamination of FFP is not always known. This case highlights that
transfusion of FFP is a stimulus for RBC antibodies and that when a
patient has had a recent transfusion of FFP, consideration should be
given to obtaining a sample for pretransfusion testing within 3 days
before a scheduled RBC transfusion. In addition, the D status of FFP
should be considered before administering FFP to premenopausal
D– women. Immunohematology 2005;21:149–51.
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On rare occasions FFP can generate an immune
response to RBC antigens. The literature includes
reports of anti-D,1–3 -Fya,3 -E,4 and -Jka 4 being identified
or increasing in titer after transfusion of as few as two
units of FFP. The Council of Europe (CE) set guidelines
in 20045 for maximum levels of RBC contamination in
FFP in an attempt to circumvent immunization by RBC
antigens. However, there is considerable variation
internationally in the method of production and the
level and assessment of RBC contamination of FFP.6 We
describe a patient who developed anti-D after the
transfusion of D+ FFP.
Case Report
A 63-year-old man was diagnosed in May 2003 with
locally extensive adenocarcinoma of the esophagus.
Laser therapy and single-fraction radiotherapy were
applied to the esophagus for control of dysphagia and
bleeding. Cytotoxic chemotherapy with fluorouracil
plus epirubicin and cisplatin from June to December
2003 resulted in significant reduction in the size of the
tumor. The patient’s warfarin therapy,administered after
aortic valve replacement in 2002, was maintained when
possible. The patient’s RBCs typed as group B, D– and
from March to August 2003 he was transfused with a
total of 21 units of group B, D– or group O, D– RBCs for
anemia. No atypical RBC antibodies were detected
during this time. On February 12, 2004, the patient
presented to the emergency department with acute
gastrointestinal hemorrhage. The patient’s Hb was 6.0
g/dL and the International Normalized Ratio was 8.9. No
atypical RBC antibodies were detected in the patient’s
plasma and he was transfused over a 15-hour period
with seven units of D– RBCs and six units of FFP, four of
which were D+ (Table 1). Endoscopy and computerized
tomography scan showed regrowth and progression of
the tumor, with extensive upper mediastinal
lymphadenopathy and a persisting pulmonary deposit.
No further blood product support was required during
this admission and the patient was discharged for
palliative care. When the patient’s sample was tested 2
months later, on April 8, the antibody screen was
positive.Anti-D, -E, and -K were identified, with reaction
strengths of 4+, 3+, and 2+, respectively, and remained
detectable on subsequent testing two months later.
Materials and Methods
Antibody identification was performed by LISS-IAT
gel cards (DiaMed AG, Switzerland) using commercial
reagent RBCs (Commonwealth Serum Laboratories,
Melbourne,Australia) diluted to 1 percent in Diamed-ID
Diluent 2. Reactions were graded from 0 (no
agglutination) to 4+ (maximum agglutination).
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Transfusion history of the patient was obtained
from the laboratory information systems at two health
care institutions. All other Western Australian
transfusion services confirmed the absence of any
transfusion history.
Discussion
This report describes the development of anti-D in
a multiply transfused D– patient after stimulation by
residual RBC antigens in D+ FFP. Anti-K and anti-E also
developed, most likely due to the transfusion of
antigen-positive RBCs (Table 1). One of the transfused
units of RBCs was K+ and,although the E phenotype of
some of the transfused units was unknown and the
incidence of the E antigen in D– Australian donors is
only 4 percent,7 the possibility that anti-E resulted from
transfusion of E+ RBCs cannot be excluded.
The D antigen is highly immunogenic: historic
experiments demonstrated primary immunization after
a cumulative dose of only 0.03 mL or 0.24 × 109 RBCs.3
For this dose, injections of 0.01 mL of whole blood
(approximately 0.005 mL RBCs) were given at 2-week
intervals. A total of six injections was administered.
The minimum volume of a single dose of RBCs
required to stimulate primary antibody sensitization is
unproved and will vary among subjects. Similarly the
number and volume of RBCs required to stimulate an
anamnestic response are uncertain, though they will be
considerably less. In an attempt to circumvent
immunization by RBC antigens, CE guidelines require
that each unit of FFP contain less than 6 × 109/L RBCs.5
Compliance would allow up to 1.5 × 109 RBCs in a 250-
mL unit of FFP, although there are often less than 0.18
× 109 RBCs.8,9 RBC stroma, as found in FFP, is less
immunogenic than intact RBCs.3 However, this and
previously reported cases1,2 implicating FFP indicate
that there is sufficient antigenicity to stimulate a
response after frozen storage and subsequent thawing
and infusion. As few as two units of FFP have been
shown to stimulate a secondary anti-D response.1,2 It is
not known whether the anti-D produced in this case
was a primary or secondary response.Although no D+
RBCs had been transfused since 2002, the possibility of
prior sensitization to D antigen cannot be completely
discounted.
Current transfusion guidelines10,11 do not require
the D status of FFP to be considered before transfusion
and CE Guidelines5 do not require FFP products to be
labeled with the Rh type. The FFP transfused in this
case was prepared from whole blood. In some
countries FFP may be subjected to pathogen reduction
with methylene blue (MB) or solvent detergent (SD).
RBC stroma is present in untreated FFP and in MBFFP,
but not in SDFFP,because it is removed by the solvent.12
This case report highlights that the D status of FFP is
relevant in transfusion practice. Specifically, a patient
who has had a recent transfusion of FFP may be
sensitized to RBC antigens, indicating the need for an
antibody screen within three days before RBC
transfusion. In addition, transfusion of D+ FFP to D–
premenopausal women may have significant
implications, and it has been reported that D– girls and
premenopausal women requiring FFP transfusion
should receive D– FFP only if SDFFP is not available.12
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